Market Research Logo

Generics in Japan

Generics in Japan

Summary

Generics in Japan industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2013-17, and forecast to 2022). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the Japan generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Key Highlights

  • For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
  • The Japanese generics market had total revenues of $25.2bn in 2017, representing a compound annual growth rate (CAGR) of 7.8% between 2013 and 2017.
  • Market consumption volume increased with a CAGR of 9.4% between 2013 and 2017, to reach a total of 70.0% in 2017.
  • The Japanese generics market is a priority for the Japanese government. Due to an aging population and the rising cost of branded drugs, healthcare policies to cut expenditure on medical costs have been implemented.
Scope
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Japan
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Japan
  • Leading company profiles reveal details of key generics market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the Japan generics market with five year forecasts by both value and volume
Reasons to buy
  • What was the size of the Japan generics market by value in 2017?
  • What will be the size of the Japan generics market in 2022?
  • What factors are affecting the strength of competition in the Japan generics market?
  • How has the market performed over the last five years?
  • How large is Japan’s generics market in relation to its regional counterparts?


Executive Summary
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Daiichi Sankyo Co Ltd
Lupin Ltd
Sawai Pharmaceutical Co Ltd
Teva Pharmaceutical Industries Limited
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine
List of Tables
Table 1: Japan generics market value: $ million, 2013-17
Table 2: Japan generics market volume: % of total pharma, 2013-17
Table 3: Japan generics market geography segmentation: $ million, 2017
Table 4: Japan generics market value forecast: $ million, 2017-22
Table 5: Japan generics market volume forecast: % of total pharma, 2017-22
Table 6: Daiichi Sankyo Co Ltd: key facts
Table 7: Daiichi Sankyo Co Ltd: key financials ($)
Table 8: Daiichi Sankyo Co Ltd: key financials (¥)
Table 9: Daiichi Sankyo Co Ltd: key financial ratios
Table 10: Lupin Ltd: key facts
Table 11: Lupin Ltd: key financials ($)
Table 12: Lupin Ltd: key financials (Rs.)
Table 13: Lupin Ltd: key financial ratios
Table 14: Sawai Pharmaceutical Co Ltd: key facts
Table 15: Sawai Pharmaceutical Co Ltd: key financials ($)
Table 16: Sawai Pharmaceutical Co Ltd: key financials (¥)
Table 17: Sawai Pharmaceutical Co Ltd: key financial ratios
Table 18: Teva Pharmaceutical Industries Limited: key facts
Table 19: Teva Pharmaceutical Industries Limited: key financials ($)
Table 20: Teva Pharmaceutical Industries Limited: key financial ratios
Table 21: Japan size of population (million), 2013-17
Table 22: Japan gdp (constant 2005 prices, $ billion), 2013-17
Table 23: Japan gdp (current prices, $ billion), 2013-17
Table 24: Japan inflation, 2013-17
Table 25: Japan consumer price index (absolute), 2013-17
Table 26: Japan exchange rate, 2013-17
List of Figures
Figure 1: Japan generics market value: $ million, 2013-17
Figure 2: Japan generics market volume: % of total pharma, 2013-17
Figure 3: Japan generics market geography segmentation: % share, by value, 2017
Figure 4: Japan generics market value forecast: $ million, 2017-22
Figure 5: Japan generics market volume forecast: % of total pharma, 2017-22
Figure 6: Forces driving competition in the generics market in Japan, 2017
Figure 7: Drivers of buyer power in the generics market in Japan, 2017
Figure 8: Drivers of supplier power in the generics market in Japan, 2017
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Japan, 2017
Figure 10: Factors influencing the threat of substitutes in the generics market in Japan, 2017
Figure 11: Drivers of degree of rivalry in the generics market in Japan, 2017
Figure 12: Daiichi Sankyo Co Ltd: revenues & profitability
Figure 13: Daiichi Sankyo Co Ltd: assets & liabilities
Figure 14: Lupin Ltd: revenues & profitability
Figure 15: Lupin Ltd: assets & liabilities
Figure 16: Sawai Pharmaceutical Co Ltd: revenues & profitability
Figure 17: Sawai Pharmaceutical Co Ltd: assets & liabilities
Figure 18: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 19: Teva Pharmaceutical Industries Limited: assets & liabilities

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report